Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Leerink Partners Raises Price Target on Ironwood Pharma (IRWD) to $14; Reiterates Market Perform
August 5, 2016 9:03 AM EDTLeerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $14.00 (from $10.00), following the company's 2Q earnings report. Linzess sales grew to $150.5m, ~2% above forecasts. Underlying sales growth of +34% was driven by 29% Rx volume growth. IRWD will launch Zurampic (gout) in October 2016. Zurampic... More
Ironwood Pharma (IRWD) Misses Q2 EPS by 1c
August 4, 2016 4:19 PM EDTIronwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $54.4 million versus the consensus estimate of $55.46 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More